

Claes Held

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2108805/claes-held-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211 papers	19,629 citations	56 h-index	139 g-index
238 ext. papers	24,559 ext. citations	9.4 avg, IF	6.02 L-index

#	Paper	IF	Citations
211	Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation-A SWEDEHEART study.. <i>PLoS ONE</i> , 2022 , 17, e0262580	3.7	0
210	Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA.. <i>Circulation</i> , 2022 ,	16.7	2
209	Independence of Clinical Events Committees: A Consensus Statement from Clinical Research Organizations.. <i>American Heart Journal</i> , 2022 , 248, 120-120	4.9	0
208	Clinical Events Classification (CEC) in Clinical Trials: Report on the Current Landscape and Future Directions - Proceedings from the CEC Summit 2018.. <i>American Heart Journal</i> , 2021 , 246, 93-93	4.9	1
207	Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120011035	6	0
206	Association between Ib blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 372-379	4.3	4
205	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021 , 233, 92-101	4.9	4
204	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20
203	Internet-Based Cognitive Behavioral Therapy for Patients Reporting Symptoms of Anxiety and Depression After Myocardial Infarction: U-CARE Heart Randomized Controlled Trial Twelve-Month Follow-up. <i>Journal of Medical Internet Research</i> , 2021 , 23, e25465	7.6	3
202	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021 , 42, 2995-3007	9.5	3
201	Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome. <i>Journal of Internal Medicine</i> , 2021 , 290, 392-403	10.8	4
200	Assessing the external validity of the VALIDATE-SWEDEHEART trial. <i>Clinical Trials</i> , 2021 , 18, 427-435	2.2	
199	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021 , 143, 438-448	16.7	36
198	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021 , 18, e1003513	11.6	14
197	Self-perceived cognitive status and cognitive challenges associated with cardiac rehabilitation management: experiences of elderly myocardial infarction patients. <i>Disability and Rehabilitation</i> , 2021 , 1-9	2.4	0
196	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
195	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021 , 52, 2494-2501	6.7	1

194	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. <i>Circulation</i> , 2021 , 144, 1024-1038	16.7	15
193	The Full Revasc (Ffr-guidance for complete non-culprit REVASCularization) Registry-based randomized clinical trial. <i>American Heart Journal</i> , 2021 , 241, 92-100	4.9	1
192	Natriuretic peptides and incident atrial fibrillation. <i>American Heart Journal</i> , 2021 , 241, 120	4.9	
191	Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. <i>Journal of the American Heart Association</i> , 2020 , 9, e015258	6	20
190	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 1395-1407	59.2	642
189	Organization of intensive cardiac care units in Europe: Results of a multinational survey. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 993-1001	4.3	4
188	Designing a Web-Based Psychological Intervention for Patients With Myocardial Infarction With Nonobstructive Coronary Arteries: User-Centered Design Approach. <i>Journal of Medical Internet Research</i> , 2020 , 22, e19066	7.6	0
187	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020 , 221, 1-8	4.9	10
186	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020 , 141, 10-20	16.7	11
185	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. <i>Circulation</i> , 2020 , 142, 546-555	16.7	5
184	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
183	Attending Heart School and long-term outcome after myocardial infarction: A decennial SWEDEHEART registry study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 145-154	3.9	5
182	Cardiac rehabilitation after acute myocardial infarction in Sweden - evaluation of programme characteristics and adherence to European guidelines: The Perfect Cardiac Rehabilitation (Perfect-CR) study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 18-27	3.9	12
181	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels <i>American Heart Journal</i> , 2020 , 225, 97-107	4.9	1
180	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
179	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019 , 381, 1309-1320	59.2	156
178	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021
177	Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1510-1518	3.9	10

176	Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance Document. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 805-819	5	15
175	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002470	5.2	13
174	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002471	5.2	14
173	Cardiac rehabilitation goal attainment after myocardial infarction with versus without diabetes: A nationwide registry study. <i>International Journal of Cardiology</i> , 2019 , 292, 19-24	3.2	3
172	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	12.3	145
171	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019 , 8, e010641	6	10
170	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 644-652	3.8	0
169	Should we consider early de-escalation of maintenance dose of antiplatelet therapy post-ACS?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 149-150	6.4	1
168	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019 , 42, 498-505	3.3	19
167	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , 2019 , 92, e1435-e1446	6.5	34
166	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
165	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019 , 208, 65-73	4.9	7
164	When do we need clinical endpoint adjudication in clinical trials?. <i>Upsala Journal of Medical Sciences</i> , 2019 , 124, 42-45	2.8	4
163	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e010641	6	28
162	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , 2018 , 39, 477-485	9.5	63
161	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. <i>Heart</i> , 2018 , 104, 1292-1299	5.1	12
160	Response to Letter: Borrow and cardiovascular events? <i>Journal of Internal Medicine</i> , 2018 , 283, 415	10.8	
159	Factors associated with emotional distress in patients with myocardial infarction: Results from the SWEDEHEART registry. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 910-920	3.9	19

158	Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease. <i>Journal of Internal Medicine</i> , 2018 , 283, 83-92	10.8	31
157	Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2018 , 196, 28-35	4.9	8
156	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	1
155	Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 72, 37-43	2.1	4
154	Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. <i>American Heart Journal</i> , 2018 , 202, 54-60	4.9	3
153	Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 856-864	5	16
152	The effect of group-based cognitive behavioral therapy on inflammatory biomarkers in patients with coronary heart disease-results from the SUPRIM-trial. <i>Upsala Journal of Medical Sciences</i> , 2018 , 123, 167-173	2.8	1
151	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1666-1676	16.7	23
150	Predicting Adherence to Internet-Delivered Psychotherapy for Symptoms of Depression and Anxiety After Myocardial Infarction: Machine Learning Insights From the U-CARE Heart Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10754	7.6	19
149	Treatment Activity, User Satisfaction, and Experienced Usability of Internet-Based Cognitive Behavioral Therapy for Adults With Depression and Anxiety After a Myocardial Infarction: Mixed-Methods Study. <i>Journal of Medical Internet Research</i> , 2018 , 20, e87	7.6	13
148	Internet-Based Cognitive Behavioral Therapy for Symptoms of Depression and Anxiety Among Patients With a Recent Myocardial Infarction: The U-CARE Heart Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2018 , 20, e88	7.6	36
147	Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e009609	6	7
146	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. <i>JAMA Cardiology</i> , 2018 , 3, 1160-1166	16.2	34
145	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. <i>European Heart Journal</i> , 2018 , 39, 3766-3776	9.5	65
144	Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 155-163	4.3	1
143	Cognitive ability, lifestyle risk factors, and two-year survival in first myocardial infarction men: A Swedish National Registry study. <i>International Journal of Cardiology</i> , 2017 , 231, 13-17	3.2	5
142	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. <i>American Heart Journal</i> , 2017 , 186, 91-99	4.9	24
141	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017 , 103, 623-628	5.1	30

140	An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 53-61	4.9	25
139	Psychological mediators related to clinical outcome in cognitive behavioural therapy for coronary heart disease: A sub-analysis from the SUPRIM trial. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 917-925	3.9	5
138	Young adulthood cognitive ability predicts statin adherence in middle-aged men after first myocardial infarction: A Swedish National Registry study. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 639-646	3.9	9
137	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 534-543	18.1	69
136	Emotional distress as a predictor of statin non-adherence among Swedish first-time myocardial infarction patients, 2006-2013. <i>Journal of Psychosomatic Research</i> , 2017 , 97, 30-37	4.1	6
135	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017 , 129, 2980-2987	2.2	70
134	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
133	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017 , 63, 325-333	5.5	62
132	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
131	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1689-1700	15.1	101
130	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	10
129	Impact of Selection Bias on Estimation of Subsequent Event Risk. <i>Circulation: Cardiovascular Genetics</i> , 2017 , 10,		19
128	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017 , 38, 2813-2822	9.5	33
127	Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data. <i>BMC Medical Informatics and Decision Making</i> , 2017 , 17, 99	3.6	32
126	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017 , 38, 804-810	9.5	114
125	Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. <i>New England Journal of Medicine</i> , 2017 , 377, 1132-1142	59.2	170
124	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. <i>European Heart Journal</i> , 2017 , 38, 3056-3065	9.5	174
123	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4

122	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017 , 245, 271-276	3.2	15
121	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 813-826	15.1	58
120	Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. <i>Kidney International</i> , 2017 , 91, 216-226	9.9	14
119	P4912 Swedish cardiac rehabilitation programmes; a descriptive nationwide analysis - the perfect CR study. <i>European Heart Journal</i> , 2017 , 38,	9.5	2
118	Fifteen Challenges in Establishing a Multidisciplinary Research Program on eHealth Research in a University Setting: A Case Study. <i>Journal of Medical Internet Research</i> , 2017 , 19, e173	7.6	13
117	Temporal changes in myocardial infarction incidence rates are associated with periods of perceived psychosocial stress: A SWEDEHEART national registry study. <i>American Heart Journal</i> , 2017 , 191, 12-20	4.9	5
116	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
115	Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 88, 163-73	2.7	5
114	Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	36
113	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016 , 9, e002951	6.4	7
112	Tooth loss is independently associated with poor outcomes in stable coronary heart disease. <i>European Journal of Preventive Cardiology</i> , 2016 , 23, 839-46	3.9	28
111	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
110	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
109	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016 , 174, 60-7	4.9	3
108	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1582-90	9.5	235
107	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2016 , 202, 589-94	3.2	29
106	Invasive strategies and outcomes for non-ST-segment elevation acute coronary syndromes: a twelve-year experience from SWEDEHEART. <i>EuroIntervention</i> , 2016 , 12, 1108-1116	3.1	11
105	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. <i>Heart</i> , 2016 , 102, 926-33	5.1	43

104	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
103	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
102	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
101	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	40	272
100	Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. <i>American Heart Journal</i> , 2016 , 178, 1-8	4.9	9
99	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2135-2144	15.1	46
98	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016 , 37, 1993-2001	9.5	77
97	Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003114	6	12
96	Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. <i>American Heart Journal</i> , 2016 , 178, 176-84	4.9	5
95	Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2015 , 115, 1325-32	3	16
94	Treatment of depression and anxiety with internet-based cognitive behavior therapy in patients with a recent myocardial infarction (U-CARE Heart): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 154	2.8	24
93	Exercise capacity and muscle strength and risk of vascular disease and arrhythmia in 1.1 million young Swedish men: cohort study. <i>BMJ, The</i> , 2015 , 351, h4543	5.9	60
92	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015 , 36, 1264-72	9.5	99
91	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015 , 22, 771-8	3.9	35
90	Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	8
89	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. <i>American Heart Journal</i> , 2015 , 169, 899-905.e1	4.9	65
88	Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002314	6	13
87	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. <i>EuroIntervention</i> , 2015 , 11, 737-45	3.1	39

86	Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2111-2117	15.1	260
85	Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2014 , 129, 293-303	16.7	79
84	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363
83	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014 , 168, 68-75.e2	4.9	12
82	Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International	3.2	8
81	Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2014 , 35, 969-78	9.5	39
80	Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. <i>Heart</i> , 2014 , 100, 1762-9	5.1	34
79	Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). <i>American Heart Journal</i> , 2014 , 168, 588-96	4.9	38
78	Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014 , 3, 246-56	4.3	12
77	No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial, International Journal of Cardiology, 2014, 166, 100-2	3.2	4
76	Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1493-9	15.1	39
75	Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1048-57	15.1	38
74	Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). <i>American Journal of Cardiology</i> , 2014 , 113, 936-44	3	16
73	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014 , 124, 3692-8	2.2	124
72	Dose-response relationship of total and leisure time physical activity to risk of heart failure: a prospective cohort study. <i>Circulation: Heart Failure</i> , 2014 , 7, 701-8	7.6	28
71	Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. <i>Platelets</i> , 2014 , 25, 517-25	3.6	115
70	Annual report SWEDHEART 2012. <i>Scandinavian Cardiovascular Journal</i> , 2014 , 48 Suppl 63, 2-133	2	8
69	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 1864-72	9.5	237

68	Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". <i>Circulation</i> , 2014 , 129, e21-2	16.7	1
67	Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. <i>American Heart Journal</i> , 2014 , 168, 869-77.e1	4.9	17
66	The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDHEART). <i>Scandinavian Cardiovascular Journal</i> , 2013 , 47 Suppl 62, 1-10	2	29
65	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. <i>American Heart Journal</i> , 2013 , 166, 474-80	4.9	27
64	Do clinical factors explain persistent sex disparities in the use of acute reperfusion therapy in STEMI in Sweden and Canada?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 350-8	4.3	21
63	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013 , 20, 678-85	3.9	47
62	Use of Apixaban and Warfarin in Patients Undergoing Invasive Procedures: Insights From Aristotle. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S232-S233	3.8	3
61	Risk prediction in stable angina pectoris. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 141-51	4.6	6
60	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , 2013 , 127, 2166-76	16.7	164
59	Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. <i>European Heart Journal</i> , 2013 , 34, 3624-31	9.5	250
58	Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial. <i>European Heart Journal</i> , 2013 , 34, 4536-4536	9.5	
57	Physical activity in patients with stable coronary heart disease: an international perspective. <i>European Heart Journal</i> , 2013 , 34, 3286-93	9.5	50
56	Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRAICER) trial. <i>European Heart Journal</i> , 2013 , 34, 1723-31	9.5	34
55	Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013 , 34, P536-P536	9.5	1
54	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2012 , 366, 20-33	59.2	570
53	Improving long-term outcome after myocardial infarction. <i>Lancet, The</i> , 2012 , 380, 1290-1	40	
52	Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1623-30	15.1	66
51	In-vivo extravasation induces the expression of interleukin 1 receptor type 1 in human neutrophils. <i>Clinical and Experimental Immunology</i> , 2012 , 168, 105-12	6.2	12

50	Lessons from platelet inhibition and patient outcomes. <i>Current Opinion in Cardiology</i> , 2012 , 27, 355-60	2.1	
49	Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. <i>European Heart Journal</i> , 2012 , 33, 452-66	9.5	89
48	Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 672-84	15.1	370
47	Genetic and environmental influences on the plasma interleukin-6 concentration in patients with a recent myocardial infarction: a case-control study. <i>Journal of Interferon and Cytokine Research</i> , 2011 , 31, 259-64	3.5	30
46	Long-term effects of an expanded cardiac rehabilitation programme after myocardial infarction or coronary artery bypass surgery: a five-year follow-up of a randomized controlled study. <i>Clinical Rehabilitation</i> , 2011 , 25, 79-87	3.3	31
45	Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1677-84	27.4	271
44	Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2011 , 124, 544-54	16.7	329
43	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2011 , 32, 2933-44	9.5	262
42	Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb Therapy) comparing darapladib versus placebo in patients with coronary heart disease. <i>American Heart Journal</i> , 2010 , 160, 655-61	4.9	97
41	Plasma parathyroid hormone and risk of congestive heart failure in the community. <i>European Journal of Heart Failure</i> , 2010 , 12, 1186-92	12.3	77
40	Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. <i>Circulation</i> , 2009 , 119, 2765-71	16.7	310
39	In vivo extravasated human monocytes have an altered expression of CD16, HLA-DR, CD86, CD36 and CX(3)CR1. <i>Scandinavian Journal of Immunology</i> , 2009 , 70, 368-76	3.4	8
38	Ticagrelor versus clopidogrel in patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2009 , 361, 1045-57	59.2	4753
37	In vivo transmigrated monocytes from patients with stable coronary artery disease have a reduced expression of CD11b. <i>Clinical and Experimental Immunology</i> , 2008 , 153, 196-204	6.2	5
36	Differential index: a simple time domain heart rate variability analysis with prognostic implications in stable angina pectoris. <i>Cardiology</i> , 2008 , 111, 126-33	1.6	8
35	Effects of an expanded cardiac rehabilitation programme in patients treated for an acute myocardial infarction or a coronary artery by-pass graft operation. <i>Clinical Rehabilitation</i> , 2008 , 22, 306-18	3.3	23
34	Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). <i>Vascular Medicine</i> , 2008 , 13, 245-53	3.3	26
33	Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. <i>BMC Medical Education</i> , 2008 , 8, 25	3.3	49

32	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 645-53	4.3	63
31	Venous thromboembolism in association with features of the metabolic syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007 , 100, 679-84	2.7	28
30	Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. <i>Journal of Internal Medicine</i> , 2007 , 261, 472-9	10.8	48
29	Effects of expanded cardiac rehabilitation on psychosocial status in coronary artery disease with focus on type D characteristics. <i>Journal of Behavioral Medicine</i> , 2007 , 30, 253-61	3.6	56
28	Effects of revascularization within 14 days of hospital admission due to acute coronary syndrome on 1-year mortality in patients with previous coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2007 , 28, 316-25	9.5	18
27	Activation of peripheral and in vivo transmigrated neutrophils in patients with stable coronary artery disease. <i>Atherosclerosis</i> , 2007 , 192, 328-34	3.1	52
26	Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. <i>Circulation</i> , 2007 , 115, 1371-5	16.7	146
25	Favourable long term prognosis in stable angina pectoris: an extended follow up of the angina prognosis study in Stockholm (APSIS). <i>Heart</i> , 2006 , 92, 177-82	5.1	37
24	Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 47-53	3.8	41
23	Homocysteine lowering with folic acid and B vitamins in vascular disease. <i>New England Journal of Medicine</i> , 2006 , 354, 1567-77	59.2	1332
22	Differential index, a novel graphical method for measurements of heart rate variability. <i>International Journal of Cardiology</i> , 2005 , 98, 493-9	3.2	6
21	The impact of diabetes or elevated fasting blood glucose on cardiovascular prognosis in patients with stable angina pectoris. <i>Diabetic Medicine</i> , 2005 , 22, 1326-33	3.5	7
20	Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases?. <i>Clinical Chemistry</i> , 2004 , 50, 2136-40	5.5	162
19	Prognostic value of plasma interleukin-6 concentrations and the -174 G > C and -572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. <i>Atherosclerosis</i> , 2004 , 174, 157-63	3.1	66
18	Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis. <i>Journal of Internal Medicine</i> , 2003 , 254, 244-50	10.8	10
17	Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris. <i>British Heart Journal</i> , 2002 , 87, 415-22		51
16	Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2002 , 20, 1563-9	1.9	24
15	Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes. <i>Clinical Physiology</i> , 2001 , 21, 196-207		6

14	Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. <i>European Heart Journal</i> , 2001 , 22, 62-72	9.5	126
13	Regression of left ventricular hypertrophy in human hypertension with irbesartan. <i>Journal of Hypertension</i> , 2001 , 19, 1167-76	1.9	127
12	Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS). <i>European Heart Journal</i> , 2000 , 21, 901-10	9.5	18
11	F032: Soluble E-selectin is increased in concentric left ventricular hypertrophy and is related to septal wall thickness. <i>American Journal of Hypertension</i> , 2000 , 13, S250-S251	2.3	
10	Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. <i>Atherosclerosis</i> , 2000 , 148, 179-88	3.1	43
9	Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. <i>European Heart Journal</i> , 1999 , 20, 1039-43	9.5	62
8	Prognostic implications of ambulatory myocardial ischemia and arrhythmias and relations to ischemia on exercise in chronic stable angina pectoris (the Angina Prognosis Study in Stockholm [APSIS]). <i>American Journal of Cardiology</i> , 1999 , 84, 1151-7	3	17
7	Ischaemia during exercise and ambulatory monitoring in patients with stable angina pectoris and healthy controls. Gender differences and relationships to catecholamines. <i>European Heart Journal</i> , 1998 , 19, 578-87	9.5	12
6	Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis Study in Stockholm (APSIS). <i>Atherosclerosis</i> , 1997 , 135, 109-18	3.1	11
5	Haemostatic markers, inflammatory parameters and lipids in male and female patients in the Angina Prognosis Study in Stockholm (APSIS). A comparison with healthy controls. <i>Journal of Internal Medicine</i> , 1997 , 241, 59-69	10.8	35
4	Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm. <i>Circulation</i> , 1997 , 95, 2380-6	16.7	62
3	Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). <i>European Heart Journal</i> , 1996 , 17, 76-81	9.5	180
2	Prognosis of patients with stable angina pectoris on antianginal drug therapy. <i>American Journal of Cardiology</i> , 1996 , 77, 6D-15D	3	13
1	Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angina pectoris. <i>American Journal of Cardiology</i> , 1995 , 75, 1-6	3	67